{"mainPropery":{"diseaseId":10466,"diseaseName":"Malignant eccrine spiradenoma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/10466/malignant-eccrine-spiradenoma","synonyms":["Eccrine spiradenoma, malignant","MES"],"synonyms-with-source":[{"name":"Eccrine spiradenoma, malignant"},{"name":"MES"}],"identifiers":[]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=%28malignant%5BAll+Fields%5D+AND+eccrine%5BAll+Fields%5D+AND+spiradenoma%5BAll+Fields%5D%29+AND+%22loattrfree+full+text%22%5Bsb%5D' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Malignant eccrine spiradenoma. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/1062079-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:7960' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":5627,"questionText":"What is malignant eccrine spiradenoma?","answerText":"<strong>Malignant eccrine spiradenoma</strong> is a type of tumor that develops from a&nbsp;sweat gland in the skin.&nbsp; It starts as a rapidly-growing bump on&nbsp;the head or abdomen, and may cause tenderness, redness, or an open wound.[4636]&nbsp;&nbsp;The exact cause of malignant eccrine spiradenoma is unknown, though it is thought that sun exposure or problems with the immune system (<a href=\"http://www.cancer.gov/dictionary?CdrID=45727\" target=_blank>immunosuppression</a>) may contribute to the development of this tumor.[4637]&nbsp; Because malignant eccrine spiradenoma is quite rare, there are no established treatment guidelines; however,&nbsp;in practice,&nbsp;surgery is often performed to remove the tumor and additional treatments may follow, depending on the severity and extent of the cancer.[4636][4637] ","dateModified":"2011-11-14T07:31:00"},"basicQuestions":[{"questionId":5629,"questionText":"What is the prognosis for individuals diagnosed with malignant eccrine spiradenoma?","answerText":"There is one article which reviews treatment and survival in 72 patients with malignant eccrine spiradenoma.&nbsp;&nbsp;For those patients whose cancer remained in the original location and had not spread to nearby <a href=\"http://www.cancer.gov/dictionary?CdrID=45762\" target=_blank>lymph nodes</a>, all of them were alive and disease-free during the time they were followed by their physicians&nbsp;(the follow-up time for these individuals&nbsp;ranged from six months to 12 years, with an average follow-up time of three years for the group).&nbsp;&nbsp;Of the&nbsp;patients whose tumor had spread to lymph nodes, half were alive and disease-free&nbsp;during follow-up&nbsp;(the follow-up time for these individuals&nbsp;ranged from two months to 8 years, with an average follow-up time of four years for the group).&nbsp; Survival was the lowest for those patients whose tumor had spread beyond the lymph nodes to more distant parts of the body (<a href=\"http://www.cancer.gov/dictionary?CdrID=46283\" target=_blank>metastasized</a>).[4636]","dateModified":"2011-11-14T07:31:00","resourceClassificationName":"Prognosis","references":[{"referenceId":4636,"authors":"Andreoli MT, Itani KM","articleTitle":"Malignant eccrine spiradenoma: a meta-analysis of reported cases","bookWebsiteJournalTitle":"American Journal of Surgery","date":"2011","volume":"201","pages":"695-699","url":"http://www.ncbi.nlm.nih.gov/pubmed/20851376","dateAccessed":"2011-11-08T00:00:00"}]},{"questionId":5628,"questionText":"How might malignant eccrine spiradenoma be treated?","answerText":"Surgery to remove as much of the tumor as possible is usually the first step of treatment for malignant eccrine spiradenoma.&nbsp; Both a traditional surgical&nbsp;technique known as <a href=\"http://www.cancer.gov/dictionary?CdrID=446983\" target=_blank>wide local excision</a>&nbsp;and the newer <a href=\"http://www.cancer.gov/dictionary?CdrID=442898\" target=_blank>Mohs micrographic surgery</a> are thought to be effective for treating this cancer.&nbsp; Additional treatment may include <a href=\"http://www.cancer.gov/dictionary?CdrID=44971\" target=_blank>radiation therapy</a> to destroy any cancer cells that might remain after surgery.&nbsp; Though <a href=\"http://www.cancer.gov/dictionary?CdrID=45214\" target=_blank>chemotherapy</a> has been used in cases of malignant eccrine spiradenoma, it&nbsp;is thought&nbsp;to be of limited help in treating this disease.[4636]","dateModified":"2011-11-14T07:31:00","resourceClassificationName":"Treatment","references":[{"referenceId":4636,"authors":"Andreoli MT, Itani KM","articleTitle":"Malignant eccrine spiradenoma: a meta-analysis of reported cases","bookWebsiteJournalTitle":"American Journal of Surgery","date":"2011","volume":"201","pages":"695-699","url":"http://www.ncbi.nlm.nih.gov/pubmed/20851376","dateAccessed":"2011-11-08T00:00:00"}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":32885,"abbreviatedInquiry":"My best friend has just been diagnosed with&nbsp;malignant eccrine spiradenoma.&nbsp; Do you have any information about this cancer?","caseQuestions":[{"questionId":5627,"questionText":"What is malignant eccrine spiradenoma?","answerText":"<strong>Malignant eccrine spiradenoma</strong> is a type of tumor that develops from a&nbsp;sweat gland in the skin.&nbsp; It starts as a rapidly-growing bump on&nbsp;the head or abdomen, and may cause tenderness, redness, or an open wound.[4636]&nbsp;&nbsp;The exact cause of malignant eccrine spiradenoma is unknown, though it is thought that sun exposure or problems with the immune system (<a href=\"http://www.cancer.gov/dictionary?CdrID=45727\" target=_blank>immunosuppression</a>) may contribute to the development of this tumor.[4637]&nbsp; Because malignant eccrine spiradenoma is quite rare, there are no established treatment guidelines; however,&nbsp;in practice,&nbsp;surgery is often performed to remove the tumor and additional treatments may follow, depending on the severity and extent of the cancer.[4636][4637] ","dateModified":"2011-11-14T07:31:00","references":[{"referenceId":4636,"authors":"Andreoli MT, Itani KM","articleTitle":"Malignant eccrine spiradenoma: a meta-analysis of reported cases","bookWebsiteJournalTitle":"American Journal of Surgery","date":"2011","volume":"201","pages":"695-699","url":"http://www.ncbi.nlm.nih.gov/pubmed/20851376","dateAccessed":"2011-11-08T00:00:00"},{"referenceId":4637,"authors":"Kampshoff JL, Cogbill TH","articleTitle":"Unusual skin tumors: Merkel cell carcinoma, eccrine carcinoma, glomus tumors, and dermatofibrosarcoma protuberans","bookWebsiteJournalTitle":"Surgical Clinics of North America","date":"2009","volume":"89","pages":"727-738","url":"http://www.ncbi.nlm.nih.gov/pubmed/19465208","dateAccessed":"2011-11-08T00:00:00"}]},{"questionId":5628,"questionText":"How might malignant eccrine spiradenoma be treated?","answerText":"Surgery to remove as much of the tumor as possible is usually the first step of treatment for malignant eccrine spiradenoma.&nbsp; Both a traditional surgical&nbsp;technique known as <a href=\"http://www.cancer.gov/dictionary?CdrID=446983\" target=_blank>wide local excision</a>&nbsp;and the newer <a href=\"http://www.cancer.gov/dictionary?CdrID=442898\" target=_blank>Mohs micrographic surgery</a> are thought to be effective for treating this cancer.&nbsp; Additional treatment may include <a href=\"http://www.cancer.gov/dictionary?CdrID=44971\" target=_blank>radiation therapy</a> to destroy any cancer cells that might remain after surgery.&nbsp; Though <a href=\"http://www.cancer.gov/dictionary?CdrID=45214\" target=_blank>chemotherapy</a> has been used in cases of malignant eccrine spiradenoma, it&nbsp;is thought&nbsp;to be of limited help in treating this disease.[4636]","dateModified":"2011-11-14T07:31:00","resourceClassificationName":"Treatment","references":[{"referenceId":4636,"authors":"Andreoli MT, Itani KM","articleTitle":"Malignant eccrine spiradenoma: a meta-analysis of reported cases","bookWebsiteJournalTitle":"American Journal of Surgery","date":"2011","volume":"201","pages":"695-699","url":"http://www.ncbi.nlm.nih.gov/pubmed/20851376","dateAccessed":"2011-11-08T00:00:00"}]},{"questionId":5629,"questionText":"What is the prognosis for individuals diagnosed with malignant eccrine spiradenoma?","answerText":"There is one article which reviews treatment and survival in 72 patients with malignant eccrine spiradenoma.&nbsp;&nbsp;For those patients whose cancer remained in the original location and had not spread to nearby <a href=\"http://www.cancer.gov/dictionary?CdrID=45762\" target=_blank>lymph nodes</a>, all of them were alive and disease-free during the time they were followed by their physicians&nbsp;(the follow-up time for these individuals&nbsp;ranged from six months to 12 years, with an average follow-up time of three years for the group).&nbsp;&nbsp;Of the&nbsp;patients whose tumor had spread to lymph nodes, half were alive and disease-free&nbsp;during follow-up&nbsp;(the follow-up time for these individuals&nbsp;ranged from two months to 8 years, with an average follow-up time of four years for the group).&nbsp; Survival was the lowest for those patients whose tumor had spread beyond the lymph nodes to more distant parts of the body (<a href=\"http://www.cancer.gov/dictionary?CdrID=46283\" target=_blank>metastasized</a>).[4636]","dateModified":"2011-11-14T07:31:00","resourceClassificationName":"Prognosis","references":[{"referenceId":4636,"authors":"Andreoli MT, Itani KM","articleTitle":"Malignant eccrine spiradenoma: a meta-analysis of reported cases","bookWebsiteJournalTitle":"American Journal of Surgery","date":"2011","volume":"201","pages":"695-699","url":"http://www.ncbi.nlm.nih.gov/pubmed/20851376","dateAccessed":"2011-11-08T00:00:00"}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[],"EncodedName":"Malignant_eccrine_spiradenoma"}